Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Open-label Four-way Crossover Study to Compare the PK, Safety, and Tolerability of M207 3.8 mg (Administered as Two 1.9 mg Patches) at Two Different Application Locations (Upper Arm and Thigh) for 30 Minutes With Intranasal Zolmitriptan 2.5 mg and 1 Hour Wear Time (Upper Arm) in Healthy Volunteers

Trial Profile

A Randomized Open-label Four-way Crossover Study to Compare the PK, Safety, and Tolerability of M207 3.8 mg (Administered as Two 1.9 mg Patches) at Two Different Application Locations (Upper Arm and Thigh) for 30 Minutes With Intranasal Zolmitriptan 2.5 mg and 1 Hour Wear Time (Upper Arm) in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs Zolmitriptan (Primary) ; Zolmitriptan
  • Indications Migraine
  • Focus Pharmacokinetics
  • Sponsors Zosano Pharma
  • Most Recent Events

    • 30 Jan 2019 Status changed from active, no longer recruiting to completed.
    • 27 Nov 2018 Status changed from recruiting to active, no longer recruiting.
    • 01 Nov 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top